The Trump administration is pressuring pharmaceutical companies to negotiate drug prices comparable to other wealthy nations, invoking a 'most-favored nation' clause. Despite awaiting drug and pricing details, the Department of HHS has urged pharma to begin negotiations. The measure is part of wider efforts to make pharmaceutical costs more transparent and affordable, amidst reported challenges and debates involving industry and lawmakers.